CN1895393A - Halth-care composition for regulating blood fat - Google Patents
Halth-care composition for regulating blood fat Download PDFInfo
- Publication number
- CN1895393A CN1895393A CN 200610047106 CN200610047106A CN1895393A CN 1895393 A CN1895393 A CN 1895393A CN 200610047106 CN200610047106 CN 200610047106 CN 200610047106 A CN200610047106 A CN 200610047106A CN 1895393 A CN1895393 A CN 1895393A
- Authority
- CN
- China
- Prior art keywords
- halth
- care composition
- blood lipid
- extract
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A health-care composition for regulating blood fat and decreasing TC, TG and HDL is prepared from ganoderma extract, haw extract, perilla oil and phosphatide.
Description
Technical field
The present invention relates to a kind of health product, i.e. the Halth-care composition of blood lipid regulation.
Background technology
In prior art, along with the raising of living standards of the people, China's aging population constantly increase, and the present aged more than 60 years old has accounted for 10.7% of national population, reaches 1.3 hundred million more than.The quickening of rhythm of life, dietary habit are also to hyperpyrexia, high fat development.Hyperlipidemia is the key factor that the cardiovascular and cerebrovascular vessel prevalence takes place, blood circulation diseases such as coronary heart disease (CHD), hypertension, angina pectoris, hyperlipidemia and sickness rate and mortality rate present and continue the trend that rises, occupied the first place in the city, and in 70% the rural area that accounts for national population, cardiovascular and cerebrovascular disease also leaps to the 3rd, its sickness rate is up to 8%, and mortality rate accounts for 50% of general mortality rate.Therefore exploitation transfers the fat health food to have vast market prospect.In numerous health product, prescription is different, and effect is general.
Summary of the invention
The objective of the invention is to provide the Halth-care composition of the significant more blood lipid regulation of a kind of effect at above-mentioned deficiency.
Technical solution of the present invention is: the active component of the Halth-care composition of blood lipid regulation is to be made by the raw material of following weight: Ganoderma extract 45-55g, Fructus Crataegi extract 45-55g, perilla oil 300-350g, phosphatidase 12 0-30g.
Preferably: Ganoderma extract 50g, Fructus Crataegi extract 50g, perilla oil 320g, phosphatidase 12 5g.
By the suitability for industrialized production requirement, in actual production, also to add one or more medicine or health product and produce acceptable common carrier or excipient or claim adjuvant.
Based on oral formulations, as being soft capsule, capsule, tablet, granule, powder or pill or other common formulations.Preferred dosage form: soft capsule.
Soft capsule is made by the raw material and the adjuvant of following weight: Ganoderma extract 45-55g, Fructus Crataegi extract 45-55g, perilla oil 300-350g, phosphatidase 12 0-30g, edible palm oil 45-55g, vitamin E 4-6g, gelatin 200-210g, glycerol 65-75g, purified water 200-250ml makes 1000.Trade name: month miracle soft capsule.Every day 3 times, each 3.
The main effect of raw material:
1, the main functional component of sesame extract is a ganoderan, and contains several amino acids, polypeptide, steroid class, triterpenes volatile oil, alkaloid, adenosine, plurality of enzymes, also contains multiple needed by human body trace element herein.Ganoderan can reduce fibrinogen content, and the activity that weakens partial thromboplastin makes it influence the intrinsic coagulation approach, increases microcirculatory blood flow, the circulation of qi promoting that purifies the blood, blood viscosity lowering, blood sugar lowering antithrombotic and blood coagulation resisting function.
2, the Fructus Crataegi extract functional component is mainly hyperin, ursolic acid, citric acid based on Fructus Crataegi total flavones, vitamin C, vitamin B1, B2, sugar, tannin etc.Pharmaceutical research proves, its contained flavones ingredient has blood pressure lowering, increases pharmacological actions such as coronary flow, blood fat reducing, heart tonifying, arrhythmia, and contained triterpene acids also has important function such as heart tonifying, enhancing coronary flow, improvement circulation.
3, the perilla oil functional component is an alpha-linolenic acid.Alpha-linolenic acid is that human body can not self synthetic essential fatty acid, has blood lipid regulation, effect for reducing blood fat.Alpha-linolenic acid in the perilla oil can significantly reduce content of triglyceride higher in the blood, can suppress the synthetic of endogenous cholesterol.Zoopery shows that perilla oil has the effect of adjusting blood fat to hyperlipidemia rats.Perilla oil has anti thrombotic action.Experiment confirm, perilla oil can suppress the free radical of platelet and serotonin, thereby suppresses the generation of thrombotic disease.Unsaturated fatty acids such as alpha-linolenic acid have the platelet of falling AA and suppress thromboxane A 1 nucleus formation can make biologically active pdgf weaken, and effectively controls and suppresses the coagulation of platelet on tube wall, thereby reduce the formation of thrombosis.
4, vitamin E is the vitamins supplement.Vitamin E is the strongest a kind of of antioxidation in the present known nutrient, can protect the many unsaturated fatty acids in the cell membrane, intracellular nucleic acid and proteinic sulfydryl to avoid the infringement of free radical in vivo.Because vitamin E has very strong antioxidation; thereby can reduce the formation of oxidized low-density lipoprotein relevant in the body with sclerosis of blood vessels; can protect simultaneously the integrity of vascular endothelial cell, avoid platelet on blood vessel wall, to assemble, play the atherosis effect of prevention of arterial.
5, the reason of generation cardiovascular and cerebrovascular disease is the deposition of cholesterol in blood vessel wall, influences the circulation of blood, and sclerosis of blood vessels is become fragile, and elasticity weakens, due to breaking easily.Phospholipid can dissolving cholesterol, make its not or fewly on blood vessel, deposit, keep blood vessel wall softness and unobstructed blood vessel, decompose superabundant fats, promote lipid metabolism, cholesterol regulating is at people's in-vivo content, effectively reduce hypercholesterolemia, hyperlipidemia, thereby prevent and treat arteriosclerosis and coronary heart disease.
The preparation of Ganoderma extract: take by weighing Ganoderma by recipe quantity, be broken into the long section of 1cm, water decocts three times.The water extraction 3 hours that adds for the first time 10 times of amounts adds the water extraction 2 hours of 8 times of amounts for the second time, adds the water extraction 1 hour of 6 times of amounts for the third time: collecting decoction, filter, concentrate (1.05,50 ℃ of relative densities), vacuum drying is ground into the above fine powder of 100 orders, promptly.Quality control: dry≤3%, ganoderan (with glucose meter): 〉=20.5%.
The preparation of Fructus Crataegi extract: the Fructus Crataegi of getting ormal weight, adding 70% alcohol heating reflux extracts three times, 70% ethanol that adds for the first time 8 times of amounts, second and third time adds 70% ethanol of 6 times of amounts, each 2 hours, merge extractive liquid, filtered, reclaim ethanol, be concentrated into relative density and be 1.08 when (65-70 ℃ time) reclaiming extracting solution behind the ethanol, add the hydrochloric acid solution (6m01/L) with extracting solution equivalent, be heated to 95 ℃ of hydrolysis 30 minutes, put cold, filter, get filtering residue and be washed with water to after cleaning mixture is neutrality, filtering residue is put 80 ℃ of dryings, pulverize, promptly.Be dried to water content below 3% in 80 ℃ in the dry case, promptly get Fructus Crataegi extract.Be ground into the above fine powder of 100 orders.Quality control: dry≤3%, total flavones (in rutin): 〉=15.3%.
The Halth-care composition preparation method of blood lipid regulation:
1, the preparation of content: measure perilla oil, phospholipid, vitamin E, Ganoderma extract fine powder, Fructus Crataegi extract fine powder and edible brown tung oil in accordance with regulations, above-mentioned raw materials put in the container stir, grind with colloid mill, make-various compositions are dissolved in the perilla oil, sampling and measuring content, standby.
2, the preparation of soft capsule shell glue: get gelatin, glycerol and the purified water of ormal weight,, be stirred to evenly, be heated to 65-80 ℃ with purified water, the two mixing of glycerol; Under stirring state, slowly add gelatin, after the dissolving, remove the bubble in the glue fully, leave standstill insulation, standby.
3, soft capsule filling: olive-type is selected in filling on encapsulating machine, mould for use No. 8, and loading amount is the 0.5g/ grain.Drying, cleaning, packing.
Pharmacological action: pharmacodynamics test shows before clinical, and the preventative and therapeutic administration of month miracle soft capsule can make the cholesterol of hyperlipemia rabbit, and triglyceride and low-density lipoprotein white level reduce, and whole blood viscosity and plasma viscosity are reduced.Preventive administration can make hyperlipidemia rats cholesterol and triglyceride levels reduce, and high density lipoprotein is raise.Month miracle soft capsule also can make the inductive rat platelet aggregation rate of ADP reduce, and platelet adhesion rate reduces, and the thrombus weight due to the rat arteriovenous shut method is reduced, and makes the normal mouse cruor time extending.The main component perilla oil of moon miracle soft capsule puts forward from Fructus Perillae, it is rich in alpha-linolenic acid content and reaches 50～60%, α-industry fiber crops acid is found through zoopery, the this product that contains alpha-linolenic acid can make rat blood serum T-CHOL (TC), triglyceride (TG) concentration significantly descend, HDL-C and T-CHOL ratio (HDL-c/TC) are significantly raise, show that moon miracle soft capsule has the effect of fine blood lipid regulation.Moon miracle soft capsule has carried out pressing down in a large number enzymatic activity research in rat and people's hepatomicrosome and clone and purification people HMG-CoA reductase catalytic fragment, wherein the research to purification people HMG-CoA reductase catalytic zone manifests, month miracle soft capsule to press down enzymatic activity all strong than all medicines that gone on the market, it 50% presses down only 5.4nM of enzyme concentration (IC50), and pravastatin, fluvastatin (fluvastatin), simvastatin (simvastatin), the analog value of simvastatin (cerivastatin) and atorvastatin (atrvastatin) then is respectively 44.1,27.6,11.2,10.0 and 8.2nM.The above results has also obtained consistent affirmation at its statins medicine relatively in rat and the active experiment of people's hepatomicrosome.
Advantage of the present invention is: 1, bioavailability height, determined curative effect can reduce user's serum cholesterol (TC), triglyceride (TG) significantly, and remarkable high density lipoprotein increasing cholesterol (HDL).Health-care effect with fine blood lipid regulation, safety is good.2, adopt sophisticated equipment and Technology, guaranteed constant product quality and reliable.3, neat and artistic, the uncomfortable foul odour of swallowing, can cover medicine easily of outward appearance.4, sealing fully, its thickness can prevent that oxygen enters, thus can improve its stability to volatile medicine or chance air medicine apt to deteriorate, and make medicine have longer storage period.
Below in conjunction with embodiment the present invention is described in further detail.
The specific embodiment
Clinical experiment example 1:
The soft capsule of being produced by the strong space biological medicine scientific and technological development company limited in Tonghua of moon miracle can the metabolism of control agent inner lipid, reduces TC, TG, the LDL-C of hyperlipidemia patient effectively and the effect of rising HDL-C level is arranged.
The purpose of this research is to observe moon effect for reducing fat of miracle soft capsule and a side reaction, and with inositol niacinate in contrast, now is reported as follows:
Material and method
Patient source: be and breathe out the outpatient of Affiliated Hospital of medical university, all voluntary participation tests, after cleaning for two weeks, blood fat (TC＞6.0mmol/L, 2 persons up to standard all can go into group among 3 of LD＞3.5mmol/L or the TG＞2.6mmol/L), get rid of the patient that diseases such as liver, kidney or thyroid are arranged.
Medicine source: the strong space biotechnology development corporation, Ltd. in Tonghua provides a moon miracle soft capsule, every 0.5g.
Lot number: 20051105,20051106,20051107.
Inositol Hexanicotinate, Pharma Inc. produces every 0.1g, lot number 20050806 by letter friendship.Testing index: adopt patient's fasting blood in early morning and measure.Blood fat comprises: serum cholesterol (TC), triglyceride (TG), HDL-C (HDL-C) adopt (behind the phosphorus calcium acid magnesium precipitate) enzymatic assays.LDL-C is calculated by formula: LDL-C=TC-HTL-TGX0.46, APOA and APOB measure with immunoturbidimetry.LP (A) measures with ELISA.Measure liver function, kidney merit and ECG simultaneously.
Research method: take food low fat diet and cleaned for 1 week (stop using all lipid lowerers) and adopt morning fasting blood to measure blood lipid level of all patients, all people of meeting organize standard person and include observation in.Adopt single at random blind method half patient to be divided into treatment group and matched group.Oral month miracle 0.3tid of treatment group, the oral inositol niacinate 0.3tid of matched group, the mensuration observation index of taking a blood sample respectively when the 4th week of medication and the 8th week writes down untoward reaction at any time during the treatment.
Curative effect determinate standard: undertaken by clinical drug guideline (trying) standard that in July, 1993, Ministry of Public Health was announced.
Produce effects: TC decline 〉=20% or TG decline 40% 〉=or HDL rising 〉=0.26mmol/L.
Effectively: TC decline 〉=10-20% or TG decline 20-40% 〉=or HDL rising 〉=0.1-0.25TC.
Invalid: not greater than effective standard.
Worsen: TC rising 〉=10%TG rising 〉=10% or HDL decline 〉=0.1mmol/L.
The result:
1, observe patient's 246 examples altogether, 132 examples are organized in treatment, matched group 114 examples, and two groups of one data of patient relatively see Table 1, and as seen, before two groups of patient, physical data and blood lipid level compare, no significant difference.
Table 1 liang group patient physical data comparison sheet
| The example number | The man | The woman | Age (year) accompanied with hypertension (example) | Companion's coronary heart disease (example) | TC(mmol/L) | TG(mmol/L) | HDC-Cmmol /L | |
| Treatment group matched group | 13287 11475 | 45 39 | 612±9.3 60.5±10 | 99 90 | 48 36 | 6.52±0.81 6.64±0.66 | 2.81±0.48 2.51±0.66 | 1.41±0.21 1.43±0.145 |
2, after two groups of patient's medications during the 4th, 8 weeks the lipid parameter level relatively see Table 2, as seen two groups of patients' TC, TG, the equal decrease to some degree of LDL, APOB after treating, but the treatment group reduces TC, TG, LDL, APOB and rising HDL reaches significant difference, and matched group rising HDL and reduction APOB there was no significant difference.APOA1 and LPA there is no significant difference at two groups.
Blood lipid level change list before and after the table 2 liang group patient
| Blood fat | Before the treatment | 4WK | 8WK | |||
| The treatment group | Matched group | The treatment group | Matched group | The treatment group | Matched group | |
| TC TG HDL-C LDL-C ApoA ApoB LA(a) | 6.52±0.81 2.81±0.48 1.41±0.12 3.96±0.95 1.06±0.11 1.56±0.15 0.17±0.06 | 6.64±0.61 2.51±0.66 1.43±0.15 3.96±0.78 1.07±0.93 1.52±0.14 0.18±0.07 | 5.20±0.78 * 1.98±0.56 * 1.45±0.15 2.86±0.92 * 1.10±0.12 1.51±0.17 0.11±0.55 | 5.82±0.72 * 2.33±0.61 * 1.42±0.13 2.80±0.82 * 1.10±0.11 1.50±0.16 0.15±0.06 | 5.16±0.65 * 1.95±0.73 * 1.49±0.21 * 2.73±0.72 * 1.10±0.07 1.30±0.12 * 2.11±0.06 | 5.32±0.71 * 2.29±0.95 * 1.45±0.13 2.84±0.82 * 1.10±0.10 1.50±0.13 0.13±0.05 |
The T check is relatively preceding with treatment, P*＜005
3, blood fat reducing curative effect relatively.The total effective rate that TC, TG fall in the treatment group is 95.3%, 86.84%; The total effective rate 87.11% of rising HDL-C; Matched group is followed successively by 83.87%, 76.7% and 25%, two group and analyzes relatively through RIDIT, though the total effective rate of TG reducing the former be higher than the latter, do not see that significant difference sees Table 3, but the treatment group raises to HDL and the effect that reduces TC significantly is better than matched group.
Table 3 blood fat reducing curative effect is than changeing table
| Project | Group | Total routine number | Produce effects | Effectively | Invalid | Increase the weight of | The RIDIT value | Aggregate efficiency (%) |
| TC TG HDL-C | Treatment group treatment of control group group treatment of control group group matched group | 126 93 114 90 117 60 | 72 39 75 36 63 6 | 16 13 8 11 13 3 | 2 5 5 7 5 15 | 0 0 0 0 0 0 | 0.52* 0.69 0.59 0.62 0.60 * 0.81 | 95.2％ 83.87％ 86.8％ 76.73％ 87.11％ 25％ |
Analyze P Δ＞0.05, P*＜0.05 through RIDIT
4, untoward reaction
(1) the matched group 1 example posterior lip of taking medicine is twitched phenomenon, does not send out after the drug withdrawal again.The slight rising of GPT has 2 examples during 8W.
(2) liver function, kidney merit, blood glucose and three big routine examinations are all no abnormal before and after the treatment group treatment.
Discuss
Hyperlipidemia is the risk factor of cardiovascular and cerebrovascular disease, is admitted by world medical circle.Cholesterol reducing has significance to the risk factor that reduces coronary heart disease (CHD), and particularly the rising of low density lipoprotein, LDL is the principal element that coronary heart disease myocardial infarction accident incidence rate rises.Originally studies show that two groups of patients TC, TG, LDL level after treating all significantly reduce, show that moon miracle soft capsule can reduce TC, TG, APB significantly, and the HDL that significantly raises.Soybean phospholipid itself in the moon miracle soft capsule contains cholesterol and triglyceride, can suppress the synthetic of triglyceride in vivo, thereby TG is reduced, and strong emulsification rises HDL.LDL descend make blood vessel inner cholesterol, neutral fat acid be easy to get rid of external, thereby reach the effect that reduces TC, TG, LDL.Cholesterol and lecithin generate cholesterol ester under lecithin cholesterol acyltransferase (LCTA) effect, make cholesterol be difficult for being deposited in the endotheliocyte, are difficult for taking place atherosclerosis.APOB can promote combining between lipoprotein and surface of cell membrane receptor, lipoprotein is the ingredient of these receptors, the total effective rate that moon miracle soft capsule group patient can reduce TC and rising HDL is significantly higher than Inositol Hexanicotinate, can think that a moon miracle soft capsule is a kind of effective Antilipemic health food, should be widely promoted.
Embodiment 1
The active component of the Halth-care composition of blood lipid regulation is to be made by the raw material of following weight: Ganoderma extract 50g, Fructus Crataegi extract 50g, perilla oil 320g, phosphatidase 12 5g.
Embodiment 2
The active component of the Halth-care composition of blood lipid regulation is to be made by the raw material of following weight: Ganoderma extract 45g, Fructus Crataegi extract 55g, perilla oil 300g, phosphatidase 13 0g.
Embodiment 3
The active component of the Halth-care composition of blood lipid regulation is to be made by the raw material of following weight: Ganoderma extract 55g, Fructus Crataegi extract 45g, perilla oil 350g, phosphatidase 12 0g.
Embodiment 4
The Halth-care composition of blood lipid regulation, its soft capsule is: Ganoderma extract 50g, Fructus Crataegi extract 50g, perilla oil 320g, phosphatidase 12 5g, edible palm oil 50g, vitamin E 5g, gelatin 200g, glycerol 70g, purified water 200ml makes 1000.
Claims (7)
1, a kind of Halth-care composition of blood lipid regulation, the active component that it is characterized in that it are to be made by the raw material of following weight: Ganoderma extract 45-55g, Fructus Crataegi extract 45-55g, perilla oil 300-350g, phosphatidase 12 0-30g.
2,, it is characterized in that Ganoderma extract 50g, Fructus Crataegi extract 50g, perilla oil 320g, phosphatidase 12 5g according to the Halth-care composition of the described blood lipid regulation of claim 1.
3,, it is characterized in that wherein adding acceptable common carrier or excipient in one or more medicine or the health product production according to the Halth-care composition of claim 1 or 2 described blood lipid regulation.
4,, it is characterized in that being oral formulations according to the Halth-care composition of the described blood lipid regulation of claim 3.
5,, it is characterized in that being soft capsule, capsule, tablet, granule, powder or pill according to the Halth-care composition of the described blood lipid regulation of claim 4.
6, according to the Halth-care composition of the described blood lipid regulation of claim 5, it is characterized in that soft capsule is: Ganoderma extract 45-55g, Fructus Crataegi extract 45-55g, perilla oil 300-350g, phosphatidase 12 0-30g, edible palm oil 45-55g, vitamin E 4-6g, gelatin 200-210g, glycerol 65-75g, purified water 200-250ml makes 1000.
7, according to the Halth-care composition of the described blood lipid regulation of claim 6, it is characterized in that soft capsule is: Ganoderma extract 50g, Fructus Crataegi extract 50g, perilla oil 320g, phosphatidase 12 5g, edible palm oil 50g, vitamin E 5g, gelatin 200g, glycerol 70g, purified water 200ml makes 1000.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200610047106A CN1895393B (en) | 2006-06-27 | 2006-06-27 | Health-care composition for regulating blood fat |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200610047106A CN1895393B (en) | 2006-06-27 | 2006-06-27 | Health-care composition for regulating blood fat |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1895393A true CN1895393A (en) | 2007-01-17 |
| CN1895393B CN1895393B (en) | 2010-05-12 |
Family
ID=37608131
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200610047106A Expired - Fee Related CN1895393B (en) | 2006-06-27 | 2006-06-27 | Health-care composition for regulating blood fat |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1895393B (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103652837A (en) * | 2013-12-03 | 2014-03-26 | 湖北省农业科学院农产品加工与核农技术研究所 | Cell wall broken Ganoderma Lucidum spore powder-Perilla herb oil composite softgel and preparation technology thereof |
| CN104524276A (en) * | 2014-12-17 | 2015-04-22 | 北华大学 | Composition for reducing blood fat and preparation and preparation method thereof |
| CN105125755A (en) * | 2015-08-13 | 2015-12-09 | 长春康彼达科技有限公司 | Auxiliary lipid-lowering drug and preparation method thereof |
| CN105661551A (en) * | 2016-01-19 | 2016-06-15 | 吉林金恒制药股份有限公司 | Healthcare oil soft capsules for adjusting blood lipid |
| CN106418542A (en) * | 2016-09-26 | 2017-02-22 | 南京中生生物科技有限公司 | Health-care product having function of regulating blood lipids and preparation method thereof |
| ES2976318A1 (en) * | 2022-12-07 | 2024-07-29 | Hifas Da Terra S L | COMPOSITION OF AN EXTRACT OBTAINED FROM GANODERMA LUCIDUM CARPOPHORUS AND PHOSPHOLIPIDS AND ITS USES (Machine-translation by Google Translate, not legally binding) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1153025A (en) * | 1996-01-02 | 1997-07-02 | 中国北京同仁堂集团公司北京同仁堂制药厂 | New resource food tonic lucid ganoderma tea |
| CN1330345C (en) * | 2005-05-17 | 2007-08-08 | 广西梧州制药（集团）股份有限公司 | Combination of Chinese traditional medicine for treating hyperlipemia, and preparation method |
-
2006
- 2006-06-27 CN CN200610047106A patent/CN1895393B/en not_active Expired - Fee Related
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103652837A (en) * | 2013-12-03 | 2014-03-26 | 湖北省农业科学院农产品加工与核农技术研究所 | Cell wall broken Ganoderma Lucidum spore powder-Perilla herb oil composite softgel and preparation technology thereof |
| CN104524276A (en) * | 2014-12-17 | 2015-04-22 | 北华大学 | Composition for reducing blood fat and preparation and preparation method thereof |
| CN104524276B (en) * | 2014-12-17 | 2017-11-10 | 北华大学 | Blood-fat reducing composition and its preparation and preparation method |
| CN105125755A (en) * | 2015-08-13 | 2015-12-09 | 长春康彼达科技有限公司 | Auxiliary lipid-lowering drug and preparation method thereof |
| CN105661551A (en) * | 2016-01-19 | 2016-06-15 | 吉林金恒制药股份有限公司 | Healthcare oil soft capsules for adjusting blood lipid |
| CN106418542A (en) * | 2016-09-26 | 2017-02-22 | 南京中生生物科技有限公司 | Health-care product having function of regulating blood lipids and preparation method thereof |
| ES2976318A1 (en) * | 2022-12-07 | 2024-07-29 | Hifas Da Terra S L | COMPOSITION OF AN EXTRACT OBTAINED FROM GANODERMA LUCIDUM CARPOPHORUS AND PHOSPHOLIPIDS AND ITS USES (Machine-translation by Google Translate, not legally binding) |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1895393B (en) | 2010-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1895393B (en) | Health-care composition for regulating blood fat | |
| KR20060052792A (en) | Novel compounds and compositions comprising sterols and/or stanols and cholesterol biosynthesis inhibitors and use thereofin treating or preventing a variety of diseases and conditions | |
| CN103190619A (en) | Fish oil and linseed oil soft capsules and preparation method thereof | |
| CN101836725A (en) | Application of red rice residue product in preparing health-care food for lowering blood fat | |
| CN105265968B (en) | Application of sialic acid in preparation of triglyceride-reducing beverage | |
| KR20200135739A (en) | Herbal complex medication used in manufacture of pharmaceutical composition for improving metabolism of cholesterol and triglyceride | |
| CN1923227A (en) | Traditional Chinese medicinal formulation for treating ischemic cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN1323675C (en) | Novel usage of chicory aqueous extract | |
| CN1718566A (en) | Ferulaic acid and its sodium salt used for preventing and treating senile dementia medicine | |
| CN108771248A (en) | A kind of health-care food for assisting blood fat lowering full of nutrition and preparation method thereof | |
| CN101361800A (en) | Traditional Chinese medicine for reducing blood fat and enhancing effect and reducing toxin of statins medicine and preparation method thereof | |
| CN107308358A (en) | A kind of statin and the aliphatic acid of Omega 3 and vitamin complex composition | |
| CN1052386C (en) | Functional food for lowering blood-sugar, blood-lipid and blood-presure | |
| KR101054808B1 (en) | Composition for improving cholesterol containing poly-gamma glutamic acid | |
| CN1293874C (en) | Traditional chinese medicine Monascus purpureus went using Lovastatin salt as main active and its preparation component | |
| CN1583108A (en) | Health care product of hippophae rhamnoides oil | |
| CN107693598A (en) | A kind of compound preparation of reducing blood lipid and preparation method thereof | |
| JP2008088131A (en) | Anticholesteric composition | |
| CN101259126A (en) | Composition for treating hyperlipidemia and preparation thereof | |
| CN100411631C (en) | Orally administered compound antihyperlipidemic | |
| CN109364202A (en) | A kind of composition and its preparation method and application | |
| CN105707568A (en) | Alpha-linolenic acid soft capsule with function of auxiliarily lowering blood lipids and preparation method thereof | |
| US20030225001A1 (en) | Preparation of an auricularia auricula polysaccharide and its use in mammals | |
| CN108904807A (en) | Melbine complex composition and its application | |
| CN1098072C (en) | Medicinal products of superfined alpha-linolenic acid, preparing process and preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100512 Termination date: 20110627 |